News

Foresight Diagnostics & leading cancer center to present solid tumor MRD data at AACR conference

Apr 04, 2023

AURORA, Colo., April 4, 2023 /PRNewswire/ — Foresight Diagnostics, a leader in molecular cancer diagnostics, announced the presentation of a study in collaboration with a leading cancer center at the upcoming annual meeting of the American Association for Cancer Research (AACR)…

Read the full article on PR Newswire.

Share this page on social

Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

Foresight Diagnostics & leading cancer center to present solid tumor MRD data at AACR conference

Related Posts

Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

Ready to get started? See what Samba can do for you.

Subscribe to our newsletter

Explore

Company

Let’s chat

Follow us

Subscribe to our newsletter